title: The anthracyclines and the clinical practice: do all breast cancer patients benefit? Results from the NORA study.
authors.forename: M E
authors.initials: ME
authors.lastname: Cazzaniga
authors.forename: P
authors.initials: P
authors.lastname: Pronzato
authors.forename: G
authors.initials: G
authors.lastname: Mustacchi
authors.forename: A
authors.initials: A
authors.lastname: De Matteis
authors.forename: F
authors.initials: F
authors.lastname: Di Costanzo
authors.forename: E
authors.initials: E
authors.lastname: Rulli
authors.forename: I
authors.initials: I
authors.lastname: Floriani
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018943:Anthracyclines / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone